<DOC>
	<DOCNO>NCT02621489</DOCNO>
	<brief_summary>The aim study use Exenatide long-acting release ( LAR ) [ Bydureon ] minimize vascular remodel neointima formation Percutaneous Coronary Intervention ( PCI ) accelerate stent endothelialisation .</brief_summary>
	<brief_title>Effects Re-endothelialisation With Bydureon Treatment Type 2 Diabetes Subjects</brief_title>
	<detailed_description>Exenatide LAR give once-weekly ( s.c. ) dose Bydureon ( 2 mg ) add Insulin combination Metformin . If patient Insulin na√Øve ( group ) initial dose 10U ( s.c. ) bedtime start , up-titrated achieve fP-glucose level 6 mmol/l . Standard care post myocardial infarction give PCI . Primary objective : To test whether Bydureon , add Insulin Neutral Protamine Hagedorn ( NPH ) + Metformin , superior vs. Insulin NPH + Metformin alone , cover stent strut Secondary objective : To test whether Bydureon , add Insulin NPH + Metformin , superior vs. Insulin NPH + Metformin alone : cardiac endothelial function</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>1 . Patients eligible PCI application DES , due ACS . 2 . Patients know newly diagnose T2D ( type 2 diabetes diagnose accord current WHO criteria use antidiabetic drug ) 3 . Male female subject 1880 year . 4 . HbA1c ( accordingly IFCC ) 47 mmol/mol 110 mmol/mol . 5 . Signed informed consent form . 1 . Type 1 diabetes ( autoantibody positive ) . 2 . Any history receive GLP1 analogue dipeptidyl peptidase inhibitor within 6 month 3 . Known severe heart failure , classify NYHA 4 . 4 . Active myocarditis ; malfunction artificial heart valve . 5 . History ventricular tachycardia within 3 month study entry ; second thirddegree atrioventricular block . 6 . Supine systolic blood pressure &lt; 85 mm Hg &gt; 200 mm Hg screening . 7 . Primary renal impairment , creatinine clearance &lt; 45 ml/min treat metformin . 8 . Uncorrected hypokalemia hyperkalemia ( potassium &lt; 3.5 mmol/l &gt; 5.5 mmol/l ) . 9 . Significant anemia ( Hb &lt; 90 g/l ) 10 . Severe gastrointestinal disease , include gastroparesis . As judged Investigator . 11 . Body mass index ( BMI ) &gt; 45 kg/m2 . 12 . Malignant neoplasm require chemotherapy , surgery , radiation palliative therapy previous 5 year . Patients intraepithelial squamous cell carcinoma skin treat topical 5FU subject basal cell skin cancer allow enter trial . 13 . Females child bear potential pregnant , breastfeed intend become pregnant . 14 . Current drug alcohol abuse . 15 . History acute chronic pancreatitis 16 . Subjects consider Investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glucagon-like peptide-1</keyword>
	<keyword>Endothelialization</keyword>
	<keyword>Cardiac Function</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>